Market Research Reports and Industry Reports

Hepatitis C Virus Infection

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Freedom from injecting Interferon (IFN), treating major HCV genotypes WW and betting on vaccines could bring a sea of change in the treatment of HCV infection in the future. This year the first IFN-free drug options for HCV Genotype 2/3- Gileads Sofosbuvir/RBV (GS-7977, PDUFA Dec. 8, 2013) is expected to be approved and launched! By 2015 launch of Gileads Sofosbuvir/Ledipasvir (PhIII) and AbbVie/ Enantas (ABT-450r/ABT-472/ABT-333) should remove the need of IFN for GT1 genotype HCV patients as well!

Tapping the Bigger Market- ROW: Gilead is moving well towards offering the best treatment options to a broader HCV pt population WW. . Genotype 1 is common in Australia, China, Taiwan and other countries in North Asia, while genotype 6 is found in Vietnam and other Southeast Asian countries. In India and Pakistan, genotype 3 is predominant, while genotype 4 is found in Middle Eastern countries such as Egypt, Saudi Arabia and Syria. A PAN genotype effective drug is what most companies are trying to sequester in their pipeline. This report comprehensively covers the current Standard of Care, its limitations and Future options for the treatment of HCV infection.
Table 1: KEY PRODUCTS IN PIPELINE: IFN-FREE COMBINATION
Table 2 :US & EU MARKET SHARE OF HCV DRUGS IN COMBINATION WITH IFN
Table 3:KEY PIPELINE PRODUCTS VACCINE
Table 4:DATA FROM IFN-FREE COMBINATIONS
Table 5: VIRAL RESPONSE IN GENOTYPE-1 PATIENTS IFN COMBINATIONS
Table 6 :KEY ABSTRACTS OF AASLD 13
KEY MILESTONES TO 2015

List Of Tables

Figure 1 : PTS NOT CANDIDATES FOR IFN-BASED THERAPIES
Figure 2A :SOFOSBUVIR PHIII STUDY DESIGN IN GT2/3 HCV PTS IFN FREE
Figure 2B:SOFOSBUVIR PHIII STUDY DESIGN IN GT 1,4,5,6 HCV PTS IN COMBINATION WITH IFN
Figure 3A:ION-1 SOFOSBUVIR/LEDIPASVIR PHASE 3 FDC STUDY
Figure 3B:ION-2 SOFOSBUVIR/LEDIPASVIR PHASE 3 FDC STUDY
Figure 3C:ION-3 SOFOSBUVIR/LEDIPASVIR PHASE 3 FDC STUDY
Figure: 4A :HCV GENOTYPES IN DIFFERENT PARTS OF THE WORLD
Figure: 4B :HCV PREVALENCE IN DIFFERENT PARTS OF THE WORLD
Figure 5: ABBVIEs IFN-FREE COMBINATIONS PHIII DESIGNS
Figure 6 :SIMEPREVIR IFN-FREE COMBINATIONS
Chart 1A :US & EU MARKET SHARE OF HCV DRUGS IN COMBINATION WITH IFN
Chart 1B :US & EU MARKET SHARE OF IFN-FREE COMBINATION HCV DRUGS
Figure 7 :HIV & HCV CO-INFECTION
Figure 8 :DIFFERENCE BETWEEN HIV & HCV

List Of Figures

Table 1: KEY PRODUCTS IN PIPELINE: IFN-FREE COMBINATION
Table 2 :US & EU MARKET SHARE OF HCV DRUGS IN COMBINATION WITH IFN
Table 3:KEY PIPELINE PRODUCTS VACCINE
Table 4:DATA FROM IFN-FREE COMBINATIONS
Table 5: VIRAL RESPONSE IN GENOTYPE-1 PATIENTS IFN COMBINATIONS
Table 6 :KEY ABSTRACTS OF AASLD 13
KEY MILESTONES TO 2015

China Hepatitis C Virus Envelope Protein E2 Market Research Report 2018

The global Hepatitis C Virus Envelope Protein E2 market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022,

USD 3400View Report

EMEA (Europe, Middle East and Africa) Hepatitis B Virus Core Antibody Diagnostic Kits Market Report 2018

In this report, the EMEA Hepatitis B Virus Core Antibody Diagnostic Kits market is valued at USD XX million in 2017 and is expected to reach USD XX million by

USD 4000View Report

China Hepatitis C Virus Envelope Protein E2 Market Research Report 2018

The global Hepatitis C Virus Envelope Protein E2 market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022,

USD 3400View Report

Global Hepatitis C Virus Envelope Protein E2 Market Professional Survey Report 2018

This report studies Hepatitis C Virus Envelope Protein E2 in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export

USD 3500View Report

Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 1000
  • Site Licence    USD 2000
  • Enterprisewide Licence    USD 3000
$ 1000

Reports Details

Published Date : Oct 2013
No. of Pages :33
Country :Global
Category :Healthcare
Publisher :MP Advisors
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 
istanbul escort istanbul escort istanbul escort izmit escort eskisehir escort samsun escort bursa escort ankara escort konya escort adana escort gaziantep escort kayseri escort izmir escort hatay escort

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube
maltepe escort kartal escort manavgat escort manavgat side escort konya escort tuzla escort pendik escort maltepe escort maltepe escort porno